Table 3.
Multivariate analysis models for lung dose and overall survival for esophageal cancer patients.
| Factors | HR | 95% CI |
P value | ||
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Model 1 (lung V20) | Age >70 years | 1.381 | 1.062 | 1.798 | 0.016 |
| Stage III/IV | 1.595 | 1.240 | 2.053 | <0.001 | |
| Poor differentiation | 1.493 | 1.187 | 1.878 | 0.001 | |
| Surgery | 0.476 | 0.378 | 0.600 | <0.001 | |
| Heart V30 >45% | 1.413 | 1.083 | 1.845 | 0.011 | |
| Lung V20 >19% | 1.283 | 1.013 | 1.626 | 0.039 | |
| Model 2 (lung V25) | Age >70 years | 1.369 | 1.053 | 1.781 | 0.019 |
| Stage III/IV | 1.591 | 1.236 | 2.047 | <0.001 | |
| Poor differentiation | 1.489 | 1.184 | 1.874 | 0.001 | |
| Surgery | 0.476 | 0.378 | 0.600 | <0.001 | |
| Heart V30 >45% | 1.402 | 1.073 | 1.833 | 0.013 | |
| Lung V25 >13% | 1.298 | 1.023 | 1.647 | 0.032 | |
| Model 3 (mean lung dose) | Age >70 years | 1.390 | 1.069 | 1.809 | 0.014 |
| Stage III/IV | 1.577 | 1.225 | 2.028 | <0.001 | |
| Poor differentiation | 1.485 | 1.180 | 1.868 | 0.001 | |
| Surgery | 0.479 | 0.380 | 0.603 | <0.001 | |
| Heart V30 >45% | 1.402 | 1.077 | 1.826 | 0.012 | |
| Mean lung dose >10 Gy | 1.355 | 1.068 | 1.720 | 0.012 | |